PURPOSE:
This paper describes the ability of miRNA value predict oncological outcomes in CRC patients and correlates to clinical and pathologic variables.
METHODS:
We prospectively analyzed the serological expression of microRNA-21, microRNA-34a, and microRNA-126 in 37 stage II - IV CRC patients and correlate to seven fit counterparts. Serological microRNAs were extracted using the miRNeasy Mini Kit(r) (Qiagen, Hilden, Germany). Quantification of microRNAs was performed using TaqMan Master Mix(r) reagent (Applied Biosystems, USA).
RESULTS:
We obtained serological underexpression microRNA-21, microRNA-34a, and microRNA-126 in CRC group. However, miRNAs serological values do not impact prognosis. Furthermore, miRNAs was not influenced by CEA values, TNM staging, and histological subtype.
CONCLUSION:
Despite lower expression of miR-21, miR-34a and miR-126 in the CRC group, no association with poor prognosis was found.
Colonic Neoplasms. Colon; Drug Therapy; MicroRNAs; Serum
